Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Virginia Healthcare Press.
July 2025
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | 6 | |
| 7 | 8 | 9 | 10 | 11 | 12 | 13 |
| 14 | 15 | 16 | 17 | 18 | 19 | 20 |
| 21 | 22 | 23 | 24 | 25 | 26 | 27 |
| 28 | 29 | 30 | 31 |
August 2025
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
| 1 | 2 | 3 | ||||
| 4 | 5 | 6 | 7 | 8 | 9 | 10 |
| 11 | 12 | 13 | 14 | 15 | 16 | 17 |
| 18 | 19 | 20 | 21 | 22 | 23 | 24 |
| 25 | 26 | 27 | 28 | 29 | 30 | 31 |
September 2025
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | 6 | 7 |
| 8 | 9 | 10 | 11 | 12 | 13 | 14 |
| 15 | 16 | 17 | 18 | 19 | 20 | 21 |
| 22 | 23 | 24 | 25 | 26 | 27 | 28 |
| 29 | 30 |
Press releases published on August 5, 2025
Myriad Genetics Reports Second Quarter 2025 Financial Results; Raises 2025 Revenue Guidance Following Positive Business Momentum
GlobeNewswire
·
August 5, 2025
Highlights Second quarter 2025 revenue of $213.1 million increased by 1% year-over-year. Excluding previously discussed headwinds1 of $9.5 million, revenue increased 5% year-over-year. Second quarter 2025 hereditary cancer testing revenue and volume in …
Treace Announces Peer-Reviewed Publication of Four-Year Results of the ALIGN3D™ Lapiplasty® Multicenter Prospective Clinical Study
GlobeNewswire
·
August 5, 2025
PONTE VEDRA, Fla., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, …
LifeMD Reports Second Quarter 2025 Results
GlobeNewswire
·
August 5, 2025
Total revenue increased 23% year-over-year to $62.2 million; adjusted EBITDA rose 223% to $7.1 million Telehealth revenue increased 30% to $48.6 million; telehealth adjusted EBITDA rose 560% to $3.4 million Generated more than $8 million of operating cash …
OraSure Announces Second Quarter 2025 Financial Results
GlobeNewswire
·
August 5, 2025
BETHLEHEM, Pa., Aug. 05, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced its financial results for the three months ended June 30, 2025 …
Adaptive Biotechnologies Reports Second Quarter 2025 Financial Results
GlobeNewswire
·
August 5, 2025
SEATTLE, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products …
OrthoPediatrics Corp. Reports Second Quarter 2025 Financial Results and Increases Full Year 2025 Revenue Guidance
GlobeNewswire
·
August 5, 2025
WARSAW, Ind., Aug. 05, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced its financial results for the second …
Clover Health Reports Second Quarter 2025 Results; Delivering Strong Sustainable Growth
GlobeNewswire
·
August 5, 2025
Second quarter 2025 Medicare Advantage membership of 106,323, up 32% year-over-year Second quarter 2025 Total revenues of $478 million, up 34% year-over-year Second quarter 2025 profitability metrics with GAAP Net loss of $11 million, Adjusted EBITDA of $ …
Fractyl Health Reports Potent and Durable Two-Year Real-World Outcomes with Revita® Showing Sustained Weight Loss and Improved Glucose Control After a Single Procedure
GlobeNewswire
·
August 5, 2025
Two-year follow-up in Germany Real-World Registry study showed median 9.6% weight loss and 1.6% HbA1c reduction after a single Revita procedure in participants with type 2 diabetes, with no device- or procedure-related serious adverse events to date New …
Journey Medical Corporation to Announce Second Quarter 2025 Financial Results on August 12, 2025
GlobeNewswire
·
August 5, 2025
SCOTTSDALE, Ariz., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or the “Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug …
Mdxhealth Reports Preliminary Second Quarter 2025 Results, Reaches Positive Adjusted EBITDA, and Announces Acquisition of Exosome Diagnostics Business from Bio-Techne
GlobeNewswire
·
August 5, 2025
Mdxhealth Reports Preliminary Second Quarter 2025 Results, Reaches Positive Adjusted EBITDA, and Announces Acquisition of Exosome Diagnostics Business from Bio-Techne Year-over-year Q2 revenues increased by 20% to $26.6 million Adjusted EBITDA …
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
·
August 5, 2025
SAN DIEGO, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to …
BridgeBio Reports Second Quarter 2025 Financial Results and Business Updates
GlobeNewswire
·
August 5, 2025
- As of August 1, 2025, 3,751 unique patient prescriptions have been written by 1,074 unique prescribers, representing an accelerating launch driven by strong month over month growth in the crucial treatment naïve patient segment - $110.6 million in total …
SIGA Reports Financial Results for Three and Six Months Ended June 30, 2025
GlobeNewswire
·
August 5, 2025
NEW YORK, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Generated Product Revenues of $79 million for the Three Months Ended June 30 Awarded Additional Development Funding of $27 million under the BARDA 19C Contract during the Three Months Ended June 30 Corporate …
OrthoPediatrics Corp. Announces Continued Expansion of Specialty Bracing Division Into New Territories with Multiple Clinics
GlobeNewswire
·
August 5, 2025
WARSAW, Ind., Aug. 05, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced the expansion of its OrthoPediatrics …
Ultragenyx Reports Second Quarter 2025 Financial Results and Corporate Update
GlobeNewswire
·
August 5, 2025
Second quarter total revenue of $166 million, Crysvita® revenue of $120 million and Dojolvi® revenue of $23 million Reaffirm 2025 Revenue Guidance: Total revenue between $640 million to $670 million, Crysvita revenue of $460 million to $480 million, and …
Jushi Holdings Inc. Reports Second Quarter 2025 Financial Results
GlobeNewswire
·
August 5, 2025
Revenue of $65.0 million, Reflecting Year-over-Year and Sequential Growth Net Loss of $12.3 million, Compared to $17.0 million in the First Quarter of 2025 Adjusted EBITDA Increased 39.6% Quarter-over-Quarter to $13.7 million, Up From $9.8 million in Q1 …
Acumen Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 12, 2025
GlobeNewswire
·
August 5, 2025
NEWTON, Mass., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the …
Day One Reports Second Quarter 2025 Financial Results and Corporate Progress
GlobeNewswire
·
August 5, 2025
OJEMDA™ (tovorafenib) net product revenue of $33.6 million in Q2 2025, a 10% quarter-over-quarter increase OJEMDA full-year 2025 net product revenue expected to be $140 to $150 million Ended the second quarter with $453.1 million in cash, cash equivalents …
Pacira BioSciences Reports Second Quarter 2025 Financial Results
GlobeNewswire
·
August 5, 2025
-- Solid execution across corporate, clinical and commercial initiatives -- -- Several key milestones advance 5x30 path to growth -- -- Conference call today at 4:30 p.m. ET -- BRISBANE, Calif., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. ( …
IMUNON Recaps Highlights from 2025 Second Quarter Financial Results Conference Call
GlobeNewswire
·
August 5, 2025
Investors are reminded that Shareholders of record as of August 7, 2025, will receive a 15% stock dividend payment LAWRENCEVILLE, N.J., Aug. 05, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage company in Phase 3 development with its …